Lv3
330 积分 2026-01-29 加入
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
6天前
已完结
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
6天前
已完结
Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils
8天前
已完结
50484 A Phase 1, Randomized Study Evaluating the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a novel high-affinity, long-acting anti-IgE antibody (LP-003) in healthy volunteers
8天前
已完结
Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo
8天前
已关闭
Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria
8天前
已完结
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease
9天前
已完结
In Vitro Th Differentiation Protocol
9天前
已完结
A Novel Small Molecule ITK Inhibitor Suppresses Th2/Th17 Differentiation and Attenuates Airway Inflammation in a Mouse Model of HDM‐Induced Asthma
16天前
已完结
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab
24天前
已完结
皖公网安备34019202002308
